Growth hormone secretagogue: difference between revisions
Diff·revision 9 → 10·03:59, 25 Mar 2025
Difference between revision 9 and revision 10 of Growth hormone secretagogue. 2 lines changed; the page grew by 143 bytes.
| Revision 9 — 22:40, 26 Feb 2025 KPV_Kester (talk) rm the aggregate purity claim — no source, and no such survey exists 3,433 bytes +83 | Revision 10 — 03:59, 25 Mar 2025 TesamorelinTeg (talk) move the vendor-availability paragraph out; that is not article material 3,576 bytes +143 | ||
|---|---|---|---|
| 26 | The evidence base for the unapproved compounds is thin: small studies, short durations, surrogate endpoints such as growth hormone or IGF-1 concentration rather than clinical outcomes, and in several cases no controlled human data at all.{{r|sigalos2018}} | 26 | The evidence base for the unapproved compounds is thin: small studies, short durations, surrogate endpoints such as growth hormone or IGF-1 concentration rather than clinical outcomes, and in several cases no controlled human data at all.{{r|sigalos2018}} |
| 27 | 27 | ||
| + | 28 | They are prohibited in competitive sport under anti-doping rules, which is a regulatory fact rather than a safety statement.{{r|molitch2011}} | |
| + | 29 | ||
| 28 | == References == | 30 | == References == |
| 29 | {{reflist}} | 31 | {{reflist}} |